Two Decades With Omalizumab: What We Still Have to Learn

Biologics. 2018 Oct 26;12:135-142. doi: 10.2147/BTT.S180846. eCollection 2018.

Abstract

From its availability for clinical use nearly two decades ago for severe asthma, omalizumab has gained strong evidence of efficacy and safety in the treatment of severe asthma not controlled by standard-of-care therapy. It has been acknowledged by Global Initiative on Asthma guidelines as add-on therapy against severe uncontrolled asthma. Thanks to controlled trials supporting its efficacy, omalizumab has also been licensed for the treatment of chronic spontaneous urticaria. The optimal duration of treatment in either disease has not been established. Despite its high price, omalizumab appears to be cost-effective in severe uncontrolled asthma as well as in chronic urticaria. The literature suggests a wide range of applications for omalizumab in various disorders regardless of allergic or non-allergic pathophysiology.

Keywords: anti-IgE antibody; chronic spontaneous urticaria; cost-effectiveness; efficacy; omalizumab; safety; severe asthma.

Publication types

  • Review